Ty Gluckman, M.D., says the 2026 dyslipidemia guideline brings back risk-based LDL goals, and clinical inertia, not access, ...

Ty Gluckman, M.D., says undertesting and undertreatment are the biggest gaps in lipid care and calls on leaders to invest in ...

Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B ...

The chief pharmacy officer role has changed significantly over the past five years, shifting away from running operations and ...

Robotic lobectomies grew from 49% to 70% of cases from 2020 to 2024 as access and training expanded, says Staci Beamer, M.D., ...

In this month’s episode of Tuning In to the C-Suite, Managing Editor Peter Wehrwein talks with Rick Bates, MBA, president and CEO of RxSense. In his conversation with Wehrwein, Bates described RxSense ...

Structure is the first step toward better sleep for children with ADHD, according to Alison Pritchard, Ph.D., a child ...

Jamilia Sherls, DNP, MPH, RN, CPN, CDP, of Washington’s health department says health systems should look to AAP and AAFP ...

Bronchiectasis, a chronic inflammatory lung disease characterized by clinical cough, sputum production and recurrent respiratory infections, is entering the spotlight, with clinic ...

Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.

Chad Hatfield, Pharm.D., of UC Davis Health, says 340B savings fund free clinics and mental health care that could shrink as the program’s future shifts. The future of the 340B Drug Pricing Program ...

Early-stage lung cancer patients on Tagrisso are living past 8 years ...